By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Through a trust, Dudum sold about $33.4 million worth of his company’s stock on Thursday, according to a filing with the ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Current health news covers Novo Nordisk's ongoing lawsuits over Wegovy copies, influencer Michelle Miller's push for GMOs, IO Biotech's narrowly missed cancer vaccine goal, and China's ban on Spanish ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Health Hims & Hers Will Sell Wegovy-Like Weight Loss Drugs for $199 The telehealth company's stock surged after the announcement Bruce Gil, Quartz Published May 20, 2024 | Comments (13) 𝕏 ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Novo Nordisk (NVO) said on Monday that it will cease its partnership with Hims & Hers Health (NYSE: HIMS), ending the direct access to Wegovy, its weight loss drug, through NovoCare Pharmacy.

Ozempic and Wegovy carry high list prices of $935.77 and $1,349.02 respectively for a month's supply, according to the company's website. Most U.S. patients are covered by health insurance and ...

Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a new, affordable price. The company, via this offer, aims to make proven ...

Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments ...